The Modified Glasgow Prognostic Score Predicts Survival in Gastric Cancer Patients with Normal CEA and CA19-9

Table 2

Clinical and laboratory characteristics associated with overall survival.

	No. of patients	Overall survival (months); Mean (95% CI)	value^†
Sex
Male	337	75.3 (69.4–81.2)	0.685
Female	151	73.8 (65.1–82.6)
Age (years)
<65	257	70.3 (64.0–76.7)	0.573
≥65	231	76.8 (69.5–84.1)
Body mass index (kg/m^2)
<25	395	74.0 (68.4–79.7)	0.689
≥25	93	68.9 (60.4–77.4)
Tumor location
Upper third	158	60.5 (52.5–68.4)	0.001
Middle third	192	82.7 (75.1–90.3)
Lower third	138	78.1 (69.1–87.0)
Hemoglobin (g/L)
<12	212	66.3 (58.7–73.8)	0.001
≥12	276	80.8 (74.1–87.5)
White cell count (×10^9/L)
<11	476	74.8 (69.7–79.9)	0.831
≥11	12	58.9 (41.6–76.2)
Neutrophils (×10^9/L)
<75	470	75.0 (69.8–80.1)	0.570
≥7.5	18	62.8 (41.1–84.5)
Lymphocytes (×10^9/L)
<3	466	74.3 (69.1–79.5)	0.255
≥3	22	85.3 (68.0–102.7)
TNM
Ib	69	103.9 (94.7–113.1)	<0.001
II	139	83.6 (77.0–90.2)
III	161	72.4 (65.1–79.7)
IV	119	31.7 (24.3–39.1)
mGPS
0	439	76.4 (71.1–81.6)	0.001
1	23	64.9 (50.0–79.8)
2	26	37.9 (23.6–52.3)

^†Kaplan–Meier survival analysis.